However, transferring either monocytes or M(IL-13) into the Ccr2−/− mice recapitulated hepatic fibrosis, with M(IL-13) transfer at a later stage (between 3 to 5 weeks following the CCL4 challenge) showing the most prominent profibrogenic effects (Fig. 9g). The gene discussed is IL13; the disease is Hepatic fibrosis.